Результаты поиска

The prevalence of antifungal agents administration in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective study.

BackgroundInvasive fungal infections (IFIs) are chief infectious complications in patients undergoing hematopoietic stem cell transplantation (HSCT). However, the diagnosis of fungal infections is difficult, and often empiric treatment initiates. Since there is no data available on the prevalence of antifungal drugs administration in allogeneic HSCT recipients in Iran, we decided to conduct this study.MethodsThis study was a retrospective review of records of patients who received allogeneic HSCT in the Hematology-Oncology, Bone Marrow Transplantation center at Shariati Hospital in Tehran, bet

Bortezomib in the management of multiple myeloma.

Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, and anemia. On a cellular level, the disease is characterized by complex interactions between tumor cells and the surrounding bone marrow microenvironment. Understanding of the relationship between malignant plasma cells and the microenvironment has sparked ongoing efforts to develop targeted therapeutic agents for treatment of this disease. The successful development of the first-in-class small-molec

Rapid Recognition of Carfilzomib-Induced Thrombotic Microangiopathy and Early Application of Eculizumab Successfully Rescued Two Relapsed Myeloma Patients.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Реальная эффективность и терпимость комбинированной терапии на основе ixazomib в современных множественных миеломах и других плазменных новообразованиях клеток.

Ixazomib — пероральный протеазонный ингибитор для реактивной/охотничьей множественной миеломы (RRMM). Цель нашего исследования состояла в анализе эффективности и терпимости комбинированной терапии на основе ixazomib. Methods Мы провели ретроспективный анализ в одном центре 126 - пациенты с опухолью RRMM и другими плазменными клетками. 65 лет, с медианой two :: предыдущая терапия и 16.7% был тройным рефрактом. Общая доля ответивших (ОРС) 52.5%; у трехклассных пациентов, страдающих рефрактом, ОРР значительно ниже, чем у нереактивных органов контроля (см.10.5% vs. 60.2%, р 2 была увязана с более

Рециркуляция и теклистамаб в реанимированном миеломе: первый опыт у двух пациентов с обширной болезнью, прошедших курс интенсивной терапии.

Цель этой статьи состоит в том, чтобы рассказать о нашем первоначальном опыте использования двух пациентов с широко распространенной множественной миеломой, в том числе с рецидивом печени и менингелия, соответственно, с использованием двух специфической T-клеточной антерпрайзерной текклистамбы с соответствующей радиотерапией, включая рентгеновское облучение. Это ретроспективная оценка данных о пациентах в одном учреждении. Оба пациента ранее получали несколько линий системной терапии и радиотерапии по нескольким целевым показателям, в результате чего по завершении последних курсов в 2025 году

New Therapeutic Strategies for Adult Acute Myeloid Leukemia.

Acute myeloid leukemia (AML) is a genetically heterogeneous hematological malignancy. Chromosomal and genetic analyses are important for the diagnosis and prognosis of AML. Some patients experience relapse or have refractory disease, despite conventional cytotoxic chemotherapies and allogeneic transplantation, and a variety of new agents and treatment strategies have emerged. After over 20 years during which no new drugs became available for the treatment of AML, the CD33-targeting antibody-drug conjugate gemtuzumab ozogamicin was developed. This is currently used in combination with standard

Совпадение в полном тексте источника
… The proportions of patients who had received red blood cell and platelet transfusions prior to therapy initiation were 54.2% and 55.9% in the venetoclax and placebo arms, respectively. … The proportions of patients who had received red blood cell and platelet transfusions before the start of treatment were 74.4% and 36.5%, for the venetoclax and placebo groups, respectively. …

A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma.

Renal dysfunction is a common comorbidity of multiple myeloma. However, tumor lysis syndrome is a rare cause of renal dysfunction in multiple myeloma. Elotuzumab is a newly US FDA-approved monoclonal antibody used in the treatment of refractory multiple myeloma. To our knowledge, elotuzumab has not been associated with a case of tumor lysis syndrome. We present the case of a patient who developed clinical tumor lysis syndrome 1 week after treatment with elotuzumab accompanied by renal failure with hyperphosphatemia, hyperkalemia, and profound hyperuricemia. His course was further complicated b

Intestinal/Multivisceral Transplantation

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

ESICM LIVES 2016: part two : Milan, Italy. 1–5 October 2016

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Understanding challenges and barriers to quality end-of-life care for patients with hematologic malignancies: a GIMEMA survey.

Patients with hematologic malignancies often receive aggressive end-of-life (EOL) care, which may be partly related to hematologists' discomfort with discontinuing aggressive treatments at EOL. It is therefore important to investigate how hematologists perceive EOL care and how this affects their clinical practice. We assessed a cohort of Italian hematological oncologists through a GIMEMA online survey to explore their attitudes toward standard measures of quality EOL care, their opinions on barriers to providing this care, and potential interventions. EOL quality measures were defined accepta

Совпадение в полном тексте источника
… Acceptability of EOL quality measures (section IV) There was more than 55% agreement on all but two EOL quality measures: no red blood cell transfusions in the last seven days of life (33%), no platelet transfusions in the last seven days of life (44%) [Figure 2 ]. …

Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review.

The use of high-dose chemotherapy with autologous support of hematopoietic progenitor cells is an effective strategy to treat various hematologic neoplasms, such as non-Hodgkin lymphomas and multiple myeloma. Mobilized peripheral blood progenitor cells are the main source of support for autologous transplants, and collection of an adequate number of hematopoietic progenitor cells is a critical step in the autologous transplant procedure. Traditional strategies, based on the use of growth factors with or without chemotherapy, have limitations even when remobilizations are performed. Granulocyte

Совпадение в полном тексте источника
… Some data show that the use of ≥5 × 10 6 CD34 + cells/kg leads to quicker and more predictable grafting, achieving platelet transfusions independence significantly earlier with potential reductions in transplant costs. 16 , 17 Thus, adequate progenitor cell mobilization is a key step when planning an …

Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment.

Cancer patients represent a growing population with drastically difficult care and a lowered quality of life, especially due to the heightened risk of vast complications. Thus, it is well established so far that one of the most prominent complications in individuals with cancer is venous thromboembolism. Since there are various improved methods for screening and diagnosing cancer and its complications, the incidence of cancer-associated thrombosis has been on the rise in recent years. Therefore, the high mortality and morbidity rates among these patients are not a surprise. Consequently, there

Management of Potential Organ Donor: Indian Society of Critical Care Medicine-Position Statement.

This position statement is documented based on the input from all contributing coauthors from the Indian Society of Critical Care Medicine (ISCCM), following a comprehensive literature review and summary of current scientific evidence. Its objective is to provide the standard perspective for the management of potential organ/tissue donors after brain death (BD) in adults only, regardless of the availability of technology. This document should only be used for guidance only and is not a substitute for proper clinical decision making in particular circumstances of any case. Endorsement by the IS

Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.

Belantamab mafodotin, a B-cell maturation antigen-targeting antibody-drug conjugate (ADC), was investigated in Japanese patients with relapsed/refractory multiple myeloma in Part 1 of the phase I DREAMM-11 study. Patients who had received ≥ 2 prior lines of therapy including a proteasome inhibitor and immunomodulatory agent were eligible. Eight patients received belantamab mafodotin monotherapy at 2.5 mg/kg (n = 4) or 3.4 mg/kg (n = 4) by intravenous infusion every 3 weeks on day 1 of each cycle until disease progression or unacceptable toxicity. Primary objectives were tolerability and safety

Review of Paraneoplastic Syndromes in Children with Malignancy.

A paraneoplastic syndrome (PNS) is a set of symptoms and signs that can accompany the formation of a cancer but is not due to its direct infiltration or metastasis. PNS results from the secretion of peptides or hormones by tumor cells or from an immunological cross-reaction between the tumor antigens and host antigens. In the adult population, PNS affects up to 15% of patients with cancer, but data on pediatric patients remain lacking. The remarkable fact is that PNS can precede an oncology diagnosis, even by months or years. PNS can involve virtually any organ of the human body. In children,

Mechanisms and management of CAR T toxicity.

Chimeric antigen receptor (CAR) T cell therapies have dramatically improved treatment outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. Despite unprecedented efficacy, treatment with CAR T cell therapies can cause a multitude of adverse effects which require monitoring and management at specialized centers and contribute to morbidity and non-relapse mortality. Such toxicities include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, neuro

Safety, Precautions, and Modalities in Cancer Rehabilitation: an Updated Review.

Purpose of reviewProviding rehabilitation to patients with cancer can be challenging due to the medical complexity associated with the illness and its treatments. This article provides the reader with a summary of frequently encountered medical conditions in the cancer population and associated safety considerations and precautions. An update on treatment modalities commonly used for symptom management is also presented.Recent findingsCancer and cancer treatments can cause changes in multiple organ systems. Special considerations and precautions are necessary to provide safe and effective reha

Update on the optimal use of bortezomib in the treatment of multiple myeloma.

The proteasome inhibitor (PI) "bortezomib" has now been in routine clinical practice for over a decade. It is now considered an important backbone therapy for all stages of the disease, and data continue to grow to support its use in newly diagnosed patients, relapsed and relapsed/refractory disease, maintenance therapy, high risk, and renal failure. Much has been learnt about the most clinically effective way of delivering therapy, with patients often benefiting more from a triplet bortezomib combination compared to a doublet combination. It is well tolerated and can be administered in the ou

Совпадение в полном тексте источника
… To maximize the likelihood of benefit from bortezomib therapy, patients with thrombocytopenia and active disease should be supported with platelet transfusions, as clinically indicated, as they initiate therapy rather than having treatment reduced or delayed because of thrombocytopenia. …

A study on a real-world data-based VTE risk prediction model for lymphoma patients.

BackgroundPatients diagnosed with malignant tumors exhibit a markedly elevated risk of venous thromboembolism (VTE), which has a negative impact on their prognosis. Currently, there is no reliable predictive model specifically for thrombosis risk in lymphoma patients. This study aims to develop and validate a machine learning model leveraging real-world data, offering a dependable risk assessment tool for the early identification of VTE in lymphoma patients.MethodsWe retrospectively analyzed 605 hospitalized patients with lymphoma between January 2019 and June 2024. Candidate predictors includ

Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions.

Currently, multiple myeloma (MM) is a prevalent hematopoietic system malignancy, known for its insidious onset and unfavorable prognosis. Recently developed chemotherapy drugs for MM have exhibited promising therapeutic outcomes. Nevertheless, to overcome the shortcomings of traditional clinical drug treatment, such as off-target effects, multiple drug resistance, and systemic toxicity, targeted drug delivery systems are optimizing the conventional pharmaceuticals for precise delivery to designated sites at controlled rates, striving for maximal efficacy and safety, presenting a promising appr